Format

Send to

Choose Destination
Prog Cardiovasc Dis. 2017 May - Jun;59(6):542-548. doi: 10.1016/j.pcad.2017.04.005. Epub 2017 Apr 30.

Neuroprotection in the Treatment of Acute Ischemic Stroke.

Author information

1
John Ochsner Heart & Vascular Center, Ochsner Medical Center, The University of Queensland, Ochsner Clinical School, 1514 Jefferson Hwy, New Orleans, LA 70121. Electronic address: rapatel@ochsner.org.
2
St. Thomas Heart-St. Thomas Midtown Hospital, 301 21st Avenue North, Suite 100, Nashville, TN 37203.

Abstract

Neuroprotection remains one of the holy grails of acute ischemic stroke therapy. The ability to protect the ischemic brain from injury until reperfusion and then to protect the brain from reperfusion injury could theoretically improve freedom from disability among stroke survivors. This manuscript reviews the molecular and cellular pathophysiology of stroke and summarizes pharmacologic and other therapies that showed promise in pre-clinical testing as neuroprotection agents. However to date, no compelling efficacy data have been published regarding any pharmacologic or other therapies. Nonetheless the search for effective neuroprotection continues at stroke centers throughout the world.

KEYWORDS:

Glutamate; Hypothermia; Neuroprotection; Stroke; Transcranial laser therapy

PMID:
28465001
DOI:
10.1016/j.pcad.2017.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center